Invizius, an Edinburgh, Scotland, UK-based biotech company developing breakthrough treatments for patients on dialysis, raised £950k in funding.
The round was led by Mercia Ventures and supported by Calculus Capital, Syensqo, the University of Edinburgh’s Old College Capital and Scottish Enterprise.
Founded in 2018 as a spin-out from the University of Edinburgh and led by Magnus Nicolson, CEO, Invizius is a biotech company developing a ‘dialysis breakthrough’ treatment.
The company intends to use the funds to prepare for the next stage of clinical trials of its H-Guard product in continuous renal replacement therapy (CRRT), a type of dialysis used in cases of acute kidney injury in an intensive care unit (ICU), and will assess its impact in modifying the immune response and reducing renal tubule damage. H-Guard addresses the inflammatory responses that patients suffer during dialysis which can cause life-threatening complications including damage to organs and the cardiovascular system. A ‘First in Human’ study earlier this year demonstrated its safety and tolerability and produced encouraging biomarker data.
The latest funding brings the total raised to date to over £13m.
